arrow
H

Hiroaki Yanagimoto

kobe university
H指数:38
被引数:5,203

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors

肝内病灶对接受仑伐替尼或免疫检查点抑制剂治疗的肝细胞癌患者病灶特异性应答率的影响

HPB
IF2.4
2025-11-150
PRE
Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy

肝切除术后复发性肝细胞癌中肿瘤可切除标准的实用性

2025-11-010
OA
Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma

多学科策略包括局部治疗,旨在实现阿替利珠单抗联合贝伐珠单抗治疗后肝细胞癌患者的无药状态。

2025-10-010
OA
Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)

多中心回顾性研究:系统性疗法在神经内分泌肿瘤3级患者中的疗效(JOSC-2001)

2025-09-010
PRE
Outcomes of FOLFIRINOX versus Gemcitabine plus nab-Paclitaxel in Patients with Early Recurrent Pancreatic Cancer after Adjuvant S-1 Treatment: A propensity Score-matched Analysis

FOLFIRINOX与吉西他滨联合nab-紫杉醇在S-1辅助治疗后早期复发性胰腺癌患者中的疗效比较:一项倾向性评分匹配分析

2025-08-300
PRE
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

肿瘤形态与阿特珠单抗联合贝伐单抗治疗晚期肝癌疗效的关系

2024-02-144
PRE
Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202
EJSO
IF2.9
2024-02-012
PRE
ASO Visual Abstract: The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases
2023-07-120
PRE
The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases
2023-06-294
PRE